Cultural and social misconceptions and roadblocks about the use of cannabinoids persist and represent an ongoing obstacle to increasing research and therapeutic use of these compounds. This review focuses on all these aspects and of the use of these cannabinoids in the treatment of epilepsy and seeks to offer a fairly comprehensive description of the facets of cannabinoid therapy for refractory epilepsy.
https://www.cannabisclinicians.org/wp-content/uploads/2021/01/cannabis-nomenclature-kenzi-riboulet-zimouli-1.jpg8001200Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2021-11-10 17:16:512021-11-10 17:16:51Cannabinoids in the Treatment of Epilepsy: A Review
CDKL5 deficiency disorder (CDD) is associated with refractory infantile onset epilepsy, global developmental delay, and variable features that include sleep, behavioral disturbances, and movement disorders. Current treatment is primarily symptom-based and informed by experience in caring for this population.
Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.
https://www.cannabisclinicians.org/wp-content/uploads/2021/01/cannabis-nomenclature-kenzi-riboulet-zimouli-1.jpg8001200Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2021-08-03 12:09:092021-08-03 12:09:09Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial
Cannabis sativa L. is an annual herbaceous dioecious plant which was first cultivated by agricultural human societies in Asia. Over the period of time, various parts of the plant like leaf, flower, and seed were used for recreational as well as therapeutic purposes. The main chemical components of Cannabis sativa are termed as cannabinoids, among them the key psychoactive constituent is Δ-9-tetrahydrocannabinol and cannabidiol (CBD) as active nonpsychotic constituent. Upon doing extensive literature review, it was found that cannabis has been widely studied for a number of disorders. Very recently, a pure CBD formulation, named Epidiolex, got a green flag from both United States Food and Drug Administration and Drug Enforcement Administration for 2 rare types of epilepsies. This laid a milestone in medical cannabis research. This review intends to give a basic and extensive assessment, from past till present, of the ethnological, plant, chemical, pharmacological, and legal aspects of C. sativa.
https://www.cannabisclinicians.org/wp-content/uploads/2021/01/cannabis-nomenclature-kenzi-riboulet-zimouli-1.jpg8001200Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2021-05-27 14:48:542021-05-27 14:48:54Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence
Authors: Mathieu Kuchenbuch, Gianluca D’Onofrio, Nicole Chemaly, Giulia Barcia, Théo Teng, Rima Nabbout Published in Epilepsia Open July 2020 Abstract Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug-resistant in this syndrome with frequent drop attacks. In a prospective study of add-on cannabidiol (CBD), we identified…
Authors: Juliana Andrea Ponton, Kim Smyth, Elias Soumbasis, Sergio Andres Llanos, Mark Lewis, Wilhelm August Meerholz & Robert Lawrence Tanguay Published in Journal of Medical Case Reports September 2020 Abstract Background The pharmacological treatment for autism spectrum disorders is often poorly tolerated and has traditionally targeted associated conditions, with limited benefit for the core…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2020-10-05 08:40:022020-10-05 08:40:02A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report
Authors: Dustin Sulak, Russell Saneto, Bonni Goldstein Published in Epilepsy & Behavior May 2017 Abstract The widespread patient use of artisanal cannabis preparations has preceded quality validation of cannabis use for epilepsy. Neurologists and cannabinoid specialists are increasingly in a position to monitor and guide the use of herbal cannabis in epilepsy patients. We report…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2020-09-08 11:21:492020-09-08 11:21:49The present status of artisanal cannabis for the treatment of epilepsy in the United States.
Authors: Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, Manuel Guzmán European Neuropsychopharmacology, 10 February 2020
— Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2020-02-10 08:49:252020-03-24 09:08:11Possible therapeutic applications of cannabis in the neuropsychopharmacology field.
Authors: Stephanie McGrath, Lisa R. Bartner, Sangeeta Rao, Rebecca A. Packer, Daniel L. Gustafson Journal of the American Veterinary Medical Association, 1 June 2019
— OBJECTIVE: To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy. DESIGN: Randomized blinded controlled clinical trial. ANIMALS: 26 client-owned dogs with intracta…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2019-06-01 19:48:502019-06-17 06:31:50Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
Authors: José A. Crippa, Francisco S. Guimarães, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 September 2018
— Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental a…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2018-09-21 13:29:372020-03-19 13:37:02Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Authors: Juhn A. Wada, Akira Wake, Mitsumoto Sato, Michael E. Corcoran Epilepsia, September 1975
— Acute administration of delta8-tetrahydrocannabinol (delta8-THC) or delta9-THC failed to affect partially developed or fully developed kindled amygdaloid seizures in cats. However, delta9-THC was quite effective in suppressing focal AD in the stimulated amygdala when administe…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo1975-09-01 19:10:352019-06-17 10:21:42Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.